Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Pharmacogenetic DOAC dosing remains unproven for practice; leaves open the need for prospective outcome trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Raffaele Palmirotta (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: